Roncesvalles Peptides

All Articles

Browse the full research library.

alcohol use disorder
7 min read

Semaglutide for Alcohol Use Disorder: What the VA Trial Means for GLP-1 Weight Loss Patients

The VA trial testing semaglutide for alcohol use disorder could reshape understanding of GLP-1 drugs. This article examines the research, misconceptions

AOD-9604
6 min read

Semaglutide Microdosing: Low-Dose GLP-1 Research

Semaglutide microdosing explores low GLP-1 doses for weight loss, aiming to reduce misuse risks. Research is nascent, with no consensus on efficacy or

AOD-9604
8 min read

AOD-9604 and Tirzepatide Stack: Metabolic Synergy Amid FDA Scrutiny

AOD-9604 and tirzepatide are being studied for their potential metabolic synergy in targeting stubborn fat. This article examines the research, regulatory

FDA peptide panel
5 min read

Semaglutide vs. Retatrutide: FDA Panel’s Triple-Agonist Shift

The FDA peptide panel is evaluating retatrutide, a triple-agonist, against semaglutide for weight loss. Research shows retatrutide may achieve greater

AOD-9604
9 min read

Semaglutide Safety After Compounding Pharmacy Concerns

MedPage Today's investigation into compounded semaglutide revealed dosing errors and contamination risks. This article examines the research on

AOD-9604
6 min read

AOD-9604 and CJC-1295 Stack: Research on Body Recomposition

Research examines AOD-9604 and CJC-1295 for body recomposition during semaglutide use. Current data on mitigating muscle loss remain limited and